GRAIL and Fountain Health Insurance Partner to Provide Coverage of Galleri® Multi-cancer Early Detection Test

0
3

MENLO PARK, Calif., & NAPLES, Fla.–(BUSINESS WIRE)–GRAIL, LLC, a healthcare company whose mission is to detect cancer early, when it may be cured, and Fountain Health Insurance (“Fountain Health”) today announced a partnership that may offer Galleri®, GRAIL’s multi-cancer early detection (MCED) blood test, to Fountain Health customers at 100% coverage as a part of its annual wellness advantages.

“Our partnership with GRAIL is an excellent opportunity to alter the health story for hundreds of individuals by finding cancer early so we will improve outcomes. Nevertheless, saving the lifetime of an worker or loved one is what truly will make this transformative. What higher gift could you give to your employees?” says Robert J. Rossiter, chief executive officer at Fountain Health.

The Galleri test is a first-of-its-kind MCED blood test. In a clinical study, the Galleri test demonstrated the flexibility to detect a shared signal from greater than 50 sorts of cancers, over 45 of which lack advisable screening tests today. Using advanced genomics and machine learning, the test also determines the origin of the cancer signal, which may then guide diagnostic workup. Early detection of cancer has been demonstrated to enhance cancer outcomes, yet today, nearly all of cancers are detected in late stages because only five cancer types have advisable screenings – breast, cervical, colon, lung and prostate cancers.

“We applaud Fountain Health for its commitment to proactive care and finding cancer earlier, when treatment is more likely to achieve success,” said Bob Ragusa, chief executive officer at GRAIL. “By offering the Galleri test and covering it at 100%, Fountain Health helps ensure more people have access to critical health information that would give a greater probability of surviving cancer, which still claims the lives of greater than 600,000 people annually within the U.S.”

About Fountain Health Insurance

Fountain Health believes that employees are an organization’s most vital asset. Investing in worker health encourages employees to take a position back in the corporate. Fountain Health provides the very best standard of coverage in large group medical health insurance. Nevertheless, the first focus at Fountain Health is on proactive care and keeping people healthy: not only does preventative health save lives by stopping illness or catching it early, while it continues to be highly treatable – it saves money. Early detection costs a fraction of finding and treating illnesses like cancer, heart disease and diabetes of their more advanced stages. Fountain Health can transform lives by transforming insurance. Fountain Health is headquartered in Naples, Fla., with a service location in Wilmington, N.C. A recent global headquarters has been announced and can soon be opened in Lake Nona, Fla. Learn more at www.fountainhealth.com.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early when it may be cured. GRAIL is targeted on alleviating the worldwide burden of cancer by developing pioneering technology to detect and discover multiple deadly cancer types early. The corporate is using the facility of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to boost the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the UK. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021.

For more information, please visit grail.com.

About Galleri®

The sooner that cancer is detected, the upper the prospect of successful outcomes. The Galleri multi-cancer early detection test can detect a shared cancer signal from greater than 50 sorts of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is situated within the body, with high accuracy to assist guide the subsequent steps to diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and ought to be used along with advisable cancer screenings resembling mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is meant to be used in individuals with an elevated risk of cancer, resembling those aged 50 or older.

For more details about Galleri, visit galleri.com.

Essential Galleri Safety Information

The Galleri test is advisable to be used in adults with an elevated risk for cancer, resembling those aged 50 or older. The Galleri test doesn’t detect all cancers and ought to be used along with routine cancer screening tests advisable by a healthcare provider. Galleri is meant to detect cancer signals and predict where within the body the cancer signal is situated. Use of Galleri just isn’t advisable in individuals who’re pregnant, 21 years old or younger, or undergoing lively cancer treatment.

Results ought to be interpreted by a healthcare provider within the context of medical history, clinical signs and symptoms. A test results of “Cancer Signal Not Detected” doesn’t rule out cancer. A test results of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to verify cancer.

If cancer just isn’t confirmed with further testing, it could mean that cancer just isn’t present or testing was insufficient to detect cancer, including attributable to the cancer being situated in a distinct a part of the body. False-positive (a cancer signal detected when cancer just isn’t present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory/Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is meant for clinical purposes.

LEAVE A REPLY

Please enter your comment!
Please enter your name here